Kite to Receive Exclusive License to Leverage Sangamo’s Gene Editing Technology in Allogeneic and Autologous Cell Therapy Programs in Oncology [22-February-2018] SANTA MONICA, Calif. and RICHMOND, Calif., Feb. 22, 2018 /PRNewswire/ -- Kite, a Gilead Company (Nasdaq: GILD) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced the companies have e
February 22, 2018
· 8 min read
